Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Nykode Therapeutics, A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer, Inovio Pharmaceuticals, A Study of IDP-001 in Advanced or Metastatic Solid Tumors.
Shares A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors, A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies, AP Biosciences, Sichuan Cancer Hospital.
Shares A Study of DM005 in Patients With Advanced Solid Tumors, Intratumoral N17350 in Advanced Solid Tumors, A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors, A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies.
Shares Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors, AREG, ING1, TiumBio.
Shares VasGene Therapeutics, MB21D2, A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors, Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors.
Shares Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors, DPYD, A Study of MT-4561 in Patients With Various Advanced Solid Tumors, Lead-212 PSV359 Therapy for Patients With Solid Tumors.
Shares Study of GV20-0251 in Participants With Solid Tumor Malignancies, CTNNA2, FBLN2, Queen Mary Hospital / University of Hong Kong.
The same record for scripts and assistants; checked 2026-09-04. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.